KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

AbCellera Biologics (ABCL) EBIT: 2019-2024

Historic EBIT for AbCellera Biologics (ABCL) over the last 6 years, with Dec 2024 value amounting to -$314.8 million.

  • AbCellera Biologics' EBIT fell 74.85% to -$66.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$237.2 million, marking a year-over-year decrease of 209.56%. This contributed to the annual value of -$314.8 million for FY2024, which is 32.70% down from last year.
  • As of FY2024, AbCellera Biologics' EBIT stood at -$314.8 million, which was down 32.70% from -$237.2 million recorded in FY2023.
  • AbCellera Biologics' EBIT's 5-year high stood at $216.5 million during FY2022, with a 5-year trough of -$314.8 million in FY2024.
  • Its 3-year average for EBIT is -$111.8 million, with a median of -$237.2 million in 2023.
  • In the last 5 years, AbCellera Biologics' EBIT skyrocketed by 3,889.92% in 2020 and then crashed by 209.56% in 2023.
  • AbCellera Biologics' EBIT (Yearly) stood at $156.0 million in 2020, then skyrocketed by 31.01% to $204.4 million in 2021, then increased by 5.92% to $216.5 million in 2022, then slumped by 209.56% to -$237.2 million in 2023, then tumbled by 32.70% to -$314.8 million in 2024.